Mereo BioPharma Group plc

Healthcare · Biotechnology · United Kingdom

Last price 0.3018 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 48.19M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an o...